{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:58:26Z","timestamp":1790873906320,"version":"4.1.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1765","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Lunsotogene parvec (Otarmeni \u2013 Regeneron), an adeno-associated viral vector-based gene therapy, has received accelerated approval from the FDA for treatment of severe-to-profound or profound sensorineural hearing loss (any frequency &gt;90 decibels hearing level [dB HL]) in patients with confirmed variants in both copies of the otoferlin (OTOF) gene. It is the first gene therapy to be approved in the US for genetic hearing loss.<\/jats:p>","DOI":"10.58347\/tml.2026.1765d","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:02:06Z","timestamp":1790870526000},"page":"e169-e169","source":"Crossref","is-referenced-by-count":0,"title":["Lunsotogene Parvec (Otarmeni) for Hearing Loss"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,10,12]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:02:06Z","timestamp":1790870526000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1765d"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":0,"journal-issue":{"issue":"1765","published-online":{"date-parts":[[2026,10,12]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1765d","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]}}}